Study wrapper · #1316
Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Editor's note
The pooled sample is large and the effect direction is consistent across subgroups by study design and diabetes status, but only some of the ten included studies are randomised - observational comparisons of these two drugs are vulnerable to who gets prescribed what. The serious-adverse-event finding (RR 1.83) deserves attention precisely because it runs against the otherwise similar tolerability profile, and it comes from event counts that meta-analyses handle less reliably than continuous outcomes. Readers should regard the 4-point weight difference as an average, not a prediction for any individual.
Plain-language abstract
This review pooled ten head-to-head studies covering 41,381 adults with overweight or obesity to compare tirzepatide against semaglutide. Tirzepatide was associated with about 4.3 percentage points more weight reduction and roughly 4.4 kg more absolute weight loss, plus a larger drop in HbA1c. It was also more likely to reach the 10, 15 and 20 percent weight-loss thresholds, though the two were similar at 5 percent. Serious adverse events were reported more often with tirzepatide, while overall and gastrointestinal side effects and discontinuation rates were comparable.